These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 38743828)

  • 21. Qualitative Ras pathway signature for cetuximab therapy reveals resistant mechanism in colorectal cancer.
    Song K; Lu H; Jin L; Wang K; Guo W; Zheng H; Li K; He C; You T; Fu Y; Yang J; Zhao W; Guo Z
    FEBS J; 2020 Dec; 287(23):5236-5248. PubMed ID: 32216031
    [TBL] [Abstract][Full Text] [Related]  

  • 22.
    Martianov AS; Mitiushkina NV; Ershova AN; Martynenko DE; Bubnov MG; Amankwah P; Yanus GA; Aleksakhina SN; Tiurin VI; Venina AR; Anuskina AA; Gorgul YA; Shestakova AD; Maidin MA; Belyaev AM; Baboshkina LS; Iyevleva AG; Imyanitov EN
    Int J Mol Sci; 2023 Mar; 24(5):. PubMed ID: 36902296
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The prognostic value of KRAS and BRAF in stage I-III colorectal cancer. A systematic review.
    Gallo G; Sena G; Vescio G; Papandrea M; Sacco R; Trompetto M; Sammarco G
    Ann Ital Chir; 2019; 90():127-137. PubMed ID: 30739887
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectors of epidermal growth factor receptor pathway: the genetic profiling ofKRAS, BRAF, PIK3CA, NRAS mutations in colorectal cancer characteristics and personalized medicine.
    Shen Y; Wang J; Han X; Yang H; Wang S; Lin D; Shi Y
    PLoS One; 2013; 8(12):e81628. PubMed ID: 24339949
    [TBL] [Abstract][Full Text] [Related]  

  • 25.
    Summers MG; Smith CG; Maughan TS; Kaplan R; Escott-Price V; Cheadle JP
    Clin Cancer Res; 2017 Jun; 23(11):2742-2749. PubMed ID: 27815357
    [No Abstract]   [Full Text] [Related]  

  • 26. Clinical utility of KRAS and BRAF mutations in a cohort of patients with colorectal neoplasms submitted for microsatellite instability testing.
    Cushman-Vokoun AM; Stover DG; Zhao Z; Koehler EA; Berlin JD; Vnencak-Jones CL
    Clin Colorectal Cancer; 2013 Sep; 12(3):168-78. PubMed ID: 23773459
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association between clinicopathological characteristics and RAS mutation in colorectal cancer.
    Rimbert J; Tachon G; Junca A; Villalva C; Karayan-Tapon L; Tougeron D
    Mod Pathol; 2018 Mar; 31(3):517-526. PubMed ID: 29052598
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Survival in stage II/III colorectal cancer is independently predicted by chromosomal and microsatellite instability, but not by specific driver mutations.
    Mouradov D; Domingo E; Gibbs P; Jorissen RN; Li S; Soo PY; Lipton L; Desai J; Danielsen HE; Oukrif D; Novelli M; Yau C; Holmes CC; Jones IT; McLaughlin S; Molloy P; Hawkins NJ; Ward R; Midgely R; Kerr D; Tomlinson IP; Sieber OM
    Am J Gastroenterol; 2013 Nov; 108(11):1785-93. PubMed ID: 24042191
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SATB2 and CDX2 are prognostic biomarkers in DNA mismatch repair protein deficient colon cancer.
    Ma C; Olevian D; Miller C; Herbst C; Jayachandran P; Kozak MM; Chang DT; Pai RK
    Mod Pathol; 2019 Jul; 32(8):1217-1231. PubMed ID: 30962505
    [TBL] [Abstract][Full Text] [Related]  

  • 30. KRAS, NRAS, BRAF, and PIK3CA mutation rates, clinicopathological association, and their prognostic value in Iranian colorectal cancer patients.
    Mirzapoor Abbasabadi Z; Hamedi Asl D; Rahmani B; Shahbadori R; Karami S; Peymani A; Taghizadeh S; Samiee Rad F
    J Clin Lab Anal; 2023 Mar; 37(5):e24868. PubMed ID: 36930789
    [TBL] [Abstract][Full Text] [Related]  

  • 31. KRAS and BRAF gene mutations and DNA mismatch repair status in Chinese colorectal carcinoma patients.
    Ye JX; Liu Y; Qin Y; Zhong HH; Yi WN; Shi XY
    World J Gastroenterol; 2015 Feb; 21(5):1595-605. PubMed ID: 25663779
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: A pooled analysis of randomised controlled trials.
    Peeters M; Kafatos G; Taylor A; Gastanaga VM; Oliner KS; Hechmati G; Terwey JH; van Krieken JH
    Eur J Cancer; 2015 Sep; 51(13):1704-13. PubMed ID: 26049686
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Can CT-based radiomics signature predict KRAS/NRAS/BRAF mutations in colorectal cancer?
    Yang L; Dong D; Fang M; Zhu Y; Zang Y; Liu Z; Zhang H; Ying J; Zhao X; Tian J
    Eur Radiol; 2018 May; 28(5):2058-2067. PubMed ID: 29335867
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Poor prognosis of KRAS or BRAF mutant colorectal liver metastasis without microsatellite instability.
    Umeda Y; Nagasaka T; Mori Y; Sadamori H; Sun DS; Shinoura S; Yoshida R; Satoh D; Nobuoka D; Utsumi M; Yoshida K; Yagi T; Fujiwara T
    J Hepatobiliary Pancreat Sci; 2013 Feb; 20(2):223-33. PubMed ID: 23010994
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Colorectal cancer molecular classification using BRAF, KRAS, microsatellite instability and CIMP status: Prognostic implications and response to chemotherapy.
    Murcia O; Juárez M; Rodríguez-Soler M; Hernández-Illán E; Giner-Calabuig M; Alustiza M; Egoavil C; Castillejo A; Alenda C; Barberá V; Mangas-Sanjuan C; Yuste A; Bujanda L; Clofent J; Andreu M; Castells A; Llor X; Zapater P; Jover R
    PLoS One; 2018; 13(9):e0203051. PubMed ID: 30188916
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Microsatellite Instability in Greek Colorectal Carcinoma Patients: Clinicopathological and Molecular Correlations.
    Katafygiotis P; Sakellariou S; Chatziandreou I; Giannopoulou I; Thymara I; Saetta AA; Korkolopoulou P
    Anticancer Res; 2019 Nov; 39(11):6379-6387. PubMed ID: 31704871
    [TBL] [Abstract][Full Text] [Related]  

  • 37. KRAS, NRAS, BRAF signatures, and MMR status in colorectal cancer patients in North China.
    Lian SY; Tan LX; Liu XZ; Yang LJ; Li NN; Feng Q; Wang P; Wang Y; Qiao DB; Zhou LX; Sun TT; Wang L; Wu AW; Li ZW
    Medicine (Baltimore); 2023 Mar; 102(9):e33115. PubMed ID: 36862900
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genotyping of colorectal cancer for cancer precision medicine: Results from the IPH Center for Molecular Pathology.
    Jesinghaus M; Pfarr N; Endris V; Kloor M; Volckmar AL; Brandt R; Herpel E; Muckenhuber A; Lasitschka F; Schirmacher P; Penzel R; Weichert W; Stenzinger A
    Genes Chromosomes Cancer; 2016 Jun; 55(6):505-21. PubMed ID: 26917275
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genomic and prognostic heterogeneity among RAS/BRAF
    Berg KCG; Brunsell TH; Sveen A; Alagaratnam S; Bjørnslett M; Hektoen M; Brudvik KW; Røsok BI; Bjørnbeth BA; Nesbakken A; Lothe RA
    Mol Oncol; 2021 Apr; 15(4):830-845. PubMed ID: 33325154
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Prognostic Utilities of DNA Mismatch Repair Status and KRAS and BRAF Mutation in Korean Colorectal Cancer Patients: The KASID Multicenter Study.
    Kim TW; Hwang SW; Kim KO; Cha JM; Joo YE; Cho YS
    Oncology; 2023; 101(1):49-58. PubMed ID: 36191562
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.